The good, bad, and really, really ugly behind Sarepta's drug approval

The good, bad, and really, really ugly behind Sarepta's drug approval

STAT Plus: The good, the bad, and the really, really ugly behind Sarepta’s drug approval

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

What does it all mean now that the FDA has issued a surprise decision to approve Sarepta Therapeutics’ Duchenne muscular dystrophy drug?

READ MORE